Table 2.
Patient Demographics and Clinical Characteristics at 1 Year After Enrollment
| Characteristic | Patients With 1 y of Follow-up (N = 2,529) |
|---|---|
| Age, mean (SD), y | 53.6 (14.3) |
| Sex, No. (%) | … |
| Male | 505 (20.0) |
| Female | 2,024 (80.0) |
| Race, No. (%) | … |
| White | 1,809 (71.5) |
| Black | 330 (13.0) |
| Hispanic | 228 (9.0) |
| Asian or Pacific Islander | 85 (3.4) |
| Native American or Native Alaskan | 16 (0.6) |
| Other | 22 (0.9) |
| Unknown | 39 (1.5) |
| WHO group I PAH subgroup, No. (%) | … |
| Idiopathic | 1,171 (46.3) |
| Heritablea | 74 (2.9) |
| Other | 18 (0.7) |
| PAH associated with | … |
| Connective tissue disease | 649 (25.7) |
| Congenital heart disease | 244 (9.6) |
| Portal hypertension | 139 (5.5) |
| HIV | 48 (1.9) |
| Other | 186 (7.4) |
| Modified NYHA or WHO FC, No. (%)b | … |
| I | 203 (8.4) |
| II | 1,003 (41.3) |
| III | 1,116 (45.9) |
| IV | 108 (4.4) |
FC = functional class; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; WHO = World Health Organization.
a
Some, but not all, had confirmed BMPR2 or ALK1 mutations.
b
Data were missing for 99 patients.